Clinical Trials Logo

Refractory Breast Carcinoma clinical trials

View clinical trials related to Refractory Breast Carcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03207529 Completed - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Start date: June 7, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of alpelisib when given together with enzalutamide in treating patients with androgen receptor and PTEN positive breast cancer that has spread to other places in the body. Alpelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgen receptor can cause the growth of breast cancer cells. Hormone therapy using enzalutamide may fight breast cancer by lowering the amount of androgen the body makes. Giving alpelisib and enzalutamide may work better in treating patients with breast cancer.

NCT ID: NCT02152943 Completed - Clinical trials for Advanced Malignant Solid Neoplasm

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Start date: July 17, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of everolimus and trastuzumab when given together with letrozole in treating patients with hormone receptor-positive and human epidermal growth factor (EGF) receptor 2 (HER2)-positive breast cancer or other solid tumors that have spread to other places in the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by tumor cells. Immunotherapy with monoclonal antibodies, such as trastuzumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving everolimus, letrozole, and trastuzumab together may be a better treatment for breast cancer and other solid tumors than everolimus alone.